Welcome to Prestigio Registry platform
Abstracts Page
ICAR 2025
2025-05-23
The role of doravirine in the treatment of multidrug-resistant HIV: data from the PRESTIGIO Registry
T.Clemente
CROI 2025
2025-03-09
CD4 T cell counts are inversely correlated with anti-cluster A antibodies in antiretroviral therapy-treated PLWH
M.Benlarbi, J.Richard, T.Clemente, W.D.Tolbert, M.Messier-Peet, M.Pazgier, F.Maldarelli, A.Castagna, M.Durand, and A.Finzi
CROI 2025
2025-03-09
The Genetic Barrier to Resistance to LEN Is Not Affected by Non-B Subtypes or Treatment Exposure
N.Bartolini, C.Paletti, F.Giammarino, F.Saladini, I.Vicenti, L.Fiaschi, C.Biba, I.Varasi, F.Garcia, A.G. Marcelin, M.Zazzi, V.Spagnuolo, E.Focà, S.Rusconi
CROI 2025
2025-03-09
Plasma CNS Tissue Markers in Heavily Treatment-Experienced PWH in the PRESTIGIO Registry
A.Calcagno, M.Strano, R.Lolatto, R.Vercesi, A.Mandelli, M.Antonucci, V.Spagnuolo, T.Clemente, D.Francisci, G.Cenderello, O.Schioppa, L.Comi, R.Furlan, A.Castagna, P.Cinque
GLASGOW 2024
2024-11-10
Evaluation of HIV-DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under virological control: a longitudinal study from the PRESTIGIO registry
D.Armenia, V.Spagnuolo, M.C.Bellocchi, L.Galli, G.Marchegiani, T.Clemente, L.Carioti, R.Lolatto, M.Ferrara, R.Gagliardini, G.C.Marchetti, C.Torti, G.De Socio, C.Fornabaio, M.Zazzi, A.Castagna, M.M.Santoro on behalf of the PRESTIGIO Registry
GLASGOW 2024
2024-11-10
Two-fold increased risk of cardiovascular events in people with multidrug-resistant HIV: a matched cohort analysis with data from the PRESTIGIO Registry
T.Clemente, S.Diotallevi, D.Minisci, A.Di Biagio, R.Lolatto, L.Attala, G.Cenderello, A.Siribelli, C.Muccini, S.Lo Caputo, M.Tavio, R.Papaioannu Borjesson, A.Giacomelli, A.Castagna, V.Spagnuolo
GLASGOW 2024
2024-11-10
Virological Efficacy of Dolutegravir Plus Darunavir in Multi-Drug-Resistant HIV Patients: A Real-World Cohort Study with data from the PRESTIGIO Registry
F.Lagi, M.Bellomo, R.Lolatto , F.Ducci, S.Tekle Kiros, R.Papaioannu, T.Clemente, L.Calza, M.Feasi, E.Focà, A.Giacomelli, R.Gulminetti, B.Menzaghi, A.Castagna
AIDS 2024
2024-07-24
Persistence of CXCR4-tropic virus and incidence of clinical events in persons living with four-class drug resistant HIV: data from the PRESTIGIO Registry
R.Papaioannu Borjesson, S.Diotallevi, R.Lolatto, G.Cenderello, L.Comi, A.Cascio, A.Saracino, T.Clemente, M.Mazzitelli, S.Lo Caputo, D.Armenia, M.M.Santoro, A.Castagna, V.Spagnuolo, PRESTIGIO Study Group
ICAR 2024
2024-06-21
Post-translational HIV-1 integrase modification sites might be affected by complex and prolonged treatment history associated with multidrug resistance: a proof of concept study from the PRESTIGIO registry
D.Armenia, V.Spagnuolo, L.Galli, T.Clemente, R.Lolatto, D.Minisci, L.Pagnucco, R.Pincino, V.Malagnino, T.Mulas, L.Sarmati, M.Zazzi, M.M.Santoro, A.Castagna
ICAR 2024
2024-06-20
Network analysis of proviral DNA mutations in People with 4-class-resistant HIV-1: Data from the PRESTIGIO Registry
S.Diotallevi, D.Armenia, T.Clemente, F.Saladini, S.Rusconi, L.Calza, A.Cervo, M.Zazzi, R.Lolatto, M.C.Bellocchi, G.Marchegiani, L.Carioti, E.Fronti, M.Fiscon, V. Spagnuolo, A.Castagna, M.M.Santoro, L.Farina for the PRESTIGIO Registry GROUP
ICAR 2024
2024-06-19
HIV acquisition at birth does not drive T-cell dysfunction in Heavily Treatment Experienced (HTE): data from the PRESTIGIO Registry
V.Bono, C.Tincati, V.Spagnuolo, L.Galli, A.Di Biagio, M.Augello, R.Rovito, E.Garlassi, M.C.Moioli, E.Focà, A.Castagna, G.Marchetti
ICAR 2024
2024-06-19
Multidrug resistance is associated with different gene methylation in people with HIV: a matched cohort study with data from the PRESTIGIO Registry
T.Clemente, G.M.Scotti, E.Guidi, A.Cervo, S.Rusconi, G.C.Marchetti, S.Diotallevi, S.Bagaglio, R.Lolatto, M.Tavio, C.Torti, B.M.Celesia, A.Castagna, V.Spagnuolo, on the behalf of the PRESTIGIO Study Group
CROI 2024
2024-03-03
Teropavimab and Zinlirvimab Sensitivity in People Living With MDR HIV-1: PRESTIGIO Registry Data
V.Spagnuolo, L.Galli, A.Parvangada, K.J.Dunn, F.Lagi, R.Gagliardini, L.Sarmati, A.Cattelan, A.Giacomelli, M.M.Santoro, M.Zazzi, C.Callebaut, A.Castagna, L.VanderVeen
EACS 2023
2023-10-20
Risk of virological failure after drug burden reduction in non-viremic people with 4-class drug-resistant HIV: data from the PRESTIGIO Registry
T.Clemente, S.Diotallevi, R.Lolatto, R.Gagliardini, A.Giacomelli, M.Malena, M.Ferrara, A.Cervo, L.Calza, F.Maggiolo, S.Rusconi, M.M.Santoro, A.Castagna, V.Spagnuolo on behalf of the PRESTIGIO Study Group
EACS 2023
2023-10-19
Efficacy and durability of Fostemsavir-, Ibalizumab-, or Lenacapavir-including regimens in people living with a Multidrug Resistant HIV: results from the PRESTIGIO Registry
G.Torkjazi, L.Galli, R.Gagliardini, M.Feasi, S.Bonora, F.Lagi, E.Focà, G.Marchetti, A.Cervo, F.Maggiolo, R.Gulminetti, F Vichi, R.Papaioannu Borjesson, A.Castagna, V.Spagnuolo
EACS 2023
2023-10-19
Do minority resistant variants in HIV-DNA predict virological rebound in highly treatment experienced PLWH under virological control: Data from the PRESTIGIO Registry
D.Armenia, V.Spagnuolo, M.C.Bellocchi, L.Galli, L.Duca, G.Marchegiani, T.Clemente2, L.Carioti3, R.Lolatto, L.Calza, B.M.Celesia, A.Cascio, D.Francisci, A.Saracino, C.Torti , M.Zazzi, A.Castagna, M.M.Santoro on behalf of the PRESTIGIO Registry
EACS 2023
2023-10-19
Polypharmacy, anticholinergic burden, and drug-drug interaction assessment in people living with HIV harboring a 4-class resistance: data from the PRESTIGIO Registry
M.Mazzitelli, D.Pontillo, T.Clemente, A.di Biagio, G.Cenderello, S.Rusconi, B.Menzaghi, C.Fornabaio, E.Garlassi, M.Zazzi, A.Castagna, A.Cattelan
IAS 2023
2023-07-24
Heavily Treatment-Experienced (HTE) HIV-Infected Individuals with Vertical Transmission and Detectable Viremia do not Display Increased Peripheral Inflammation Markers: Data from the PRESTIGIO Registry
V.Bono, V.Spagnuolo, L.Galli, A.di Biagio, M.Augello, R.Rovito, G.Elisa, M.C.Moioli, E.Focà, C.Tincati, A.Castagna, G.Marchetti
ICAR 2023
2023-06-16
Does NGS on HIV-1 DNA improve resistance assessment in highly treatment-experienced and multi-resistant individuals under virological control? An experience from the PRESTIGIO Registry
D.Armenia, V.Spagnuolo, M.C.Bellocchi, L.Galli, L.Duca, G.Marchegiani, T.Clemente, L.Carioti, R.Lolatto, L.Calza, B.M.Celesia, A.Cascio, D.Francisci, A.Saracino, C.Torti, M.Zazzi, A.Castagna, M.M.Santoro, on behalf of the PRESTIGIO Registry
ICAR 2023
2023-06-15
Lower AIDS-related hospitalizations in women living with HIV multidrug resistance: results from the PRESTIGIO registry
R.Papaioannu Borjesson, L.Galli, R.Lolatto, B.Menzaghi, M.Feasi, R.Gulminetti, C.Fornabaio, A.M.Cattelan, S.Bonora, F.Lagi, M.Zazzi, A.Castagna, on behalf of PRESTIGIO Study Group
ICAR 2023
2023-06-15
Malignancies and MACEs in the PRESTIGIO Registry
T.Clemente, D.Pontillo, D.Minisci, A.Di Biagio, A.Galli, L.Attala, G.Cenderello, V.Malagnino, S.Lo Caputo, M.Tavio, A.Giacomelli, A.Castagna, V.Spagnuolo, on behalf of the PRESTIGIO Study Group
Observational collection of biological samples and data on clinical characteristics of PWLH.